List of Excipients in Branded Drug PEMFEXY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eagle Pharmaceuticals Inc	PEMFEXY	pemetrexed	42367-531	HYDROCHLORIC ACID	2035-10-28
Eagle Pharmaceuticals Inc	PEMFEXY	pemetrexed	42367-531	NITROGEN	2035-10-28
Eagle Pharmaceuticals Inc	PEMFEXY	pemetrexed	42367-531	PROPYLENE GLYCOL	2035-10-28

PEMFEXY Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Pemfexy is a ready-to-dilute pemetrexed injection developed by Eagle Pharmaceuticals as an alternative to reconstituted pemetrexed products. Its commercial value comes from reducing preparation steps, avoiding powder reconstitution, and supporting consistent pharmacy handling. The formulation uses a conventional aqueous vehicle with sodium chloride and tromethamine, rather than a novel delivery platform. The strongest opportunities are hospital-convenience positioning, supply reliability, contract manufacturing, regional licensing, and differentiated presentations such as lower-waste vial sizes or ready-to-administer systems.

What is Pemfexy and how is it formulated?

Pemfexy contains pemetrexed, an antifolate antineoplastic drug used with cisplatin for malignant pleural mesothelioma and as a single agent or combination therapy for nonsquamous non-small-cell lung cancer. The product is supplied as a sterile, preservative-free solution for intravenous infusion at a concentration of 25 mg/mL.[1]

The labeled inactive ingredients are:

Component	Formulation role
Sodium chloride	Isotonicity adjustment and aqueous vehicle support
Tromethamine	Buffering and pH control
Hydrochloric acid or sodium hydroxide	Final pH adjustment, where required
Water for injection	Sterile solvent

Pemfexy is supplied in single-dose vials. The product does not require reconstitution from a lyophilized powder, which is a central commercial distinction from conventional pemetrexed presentations.[1]

What excipient attributes matter for pemetrexed?

Pemetrexed is a highly potent cytotoxic compound administered intravenously. The formulation must support:

• Chemical stability during shelf life.
• Physical stability after dilution.
• Compatibility with infusion fluids.
• Acceptable pH and osmolality.
• Low particulate burden.
• Container-closure integrity.
• Safe handling in oncology pharmacies.
• Consistent withdrawal from the vial.
• A manufacturing process suitable for aseptic filling.

Tromethamine is commercially relevant because it provides buffering without relying solely on phosphate systems. Buffer selection can affect degradation pathways, pH drift, extractables and leachables, and compatibility with container materials. Sodium chloride supports physiological tonicity but also affects ionic strength and potential interactions with packaging components.

What is the commercial advantage of Pemfexy’s excipient strategy?

The excipient system is commercially important because it enables a liquid product rather than a powder requiring reconstitution. The principal value is operational, not therapeutic.

Reconstitution avoidance

Conventional pemetrexed powder products require dilution or reconstitution before infusion. A ready-to-dilute solution can reduce:

• Pharmacy preparation time.
• Manipulation of cytotoxic powder.
• Reconstitution errors.
• Use of ancillary diluent.
• Waste generated by preparation materials.
• Training burden for pharmacy staff.

These benefits are most relevant in high-volume oncology centers, centralized compounding pharmacies, and outpatient infusion networks.

Reduced preparation variability

A pre-formulated liquid standardizes the drug concentration before final dilution. This can improve process consistency across hospitals, although the product still requires dilution and handling under applicable hazardous-drug procedures.

Potential inventory advantages

A ready-to-use liquid can simplify inventory management by removing a separate reconstitution diluent. The commercial benefit depends on vial sizes, expiration dating, cold-chain requirements, and the degree of overfill. A liquid product can also reduce the number of preparation steps in hospital protocols.

Limits of the excipient advantage

The formulation does not eliminate the principal handling requirements for cytotoxic drugs. Pemfexy remains an intravenous oncology product requiring controlled preparation, appropriate personal protective equipment, and hazardous-drug waste management. It also does not create a new route of administration or alter pemetrexed’s established dosing limitations.

What formulations are protected by Pemfexy’s patent estate?

Eagle Pharmaceuticals developed Pemfexy as a differentiated liquid pemetrexed formulation. The relevant intellectual-property strategy focuses on formulation composition, stability, and manufacturing or use characteristics rather than a new active ingredient.

Publicly reported Pemfexy-related patent activity has included U.S. formulation patents associated with Eagle’s ready-to-dilute pemetrexed product. The key commercial question is whether a competing product can use the same active ingredient while avoiding the listed claims through a different buffer system, concentration, excipient ratio, container, or manufacturing process.

IP category	Relevance to Pemfexy
Composition-of-matter patent	Generally not the basis of Pemfexy differentiation because pemetrexed is an established active ingredient
Liquid formulation patent	May cover excipient selection, concentration, pH, stability, or product characteristics
Manufacturing patent	May cover solution preparation, sterilization, filling, or control of degradation
Method-of-use patent	Could relate to dosing or therapeutic use, but formulation patents are the more direct barrier
Packaging or device patent	May protect vial configuration, closure, or administration systems

Patent scope must be assessed claim by claim. A liquid pemetrexed competitor could challenge validity, argue non-infringement, or develop a formulation with a different buffer and excipient profile.

When does Pemfexy lose exclusivity?

Pemfexy does not have the same exclusivity profile as Alimta, the originator pemetrexed product. Alimta’s core active-ingredient and use-related exclusivity has largely expired, allowing multiple generic pemetrexed products to enter the U.S. market.[2]

Pemfexy’s commercial protection depends on product-specific formulation patents, FDA regulatory exclusivity, and the ability of competitors to obtain approval without infringing enforceable claims.

The FDA approved Pemfexy in February 2020 under NDA 212526.[1] The product is not a biologic and therefore has no biosimilar exclusivity framework. It is regulated as a small-molecule drug. Any competing product would generally proceed through an abbreviated new drug application or, for a differentiated formulation, a full or supplemental pathway depending on the proposed product and FDA requirements.

What is the Orange Book status of Pemfexy?

Pemfexy is an FDA-approved prescription drug listed in the Orange Book under pemetrexed injection. The Orange Book is the controlling public source for FDA-listed patents and regulatory exclusivity associated with the product.[3]

Orange Book-listed patents can create a 30-month stay if a generic applicant files a Paragraph IV certification and the patent holder brings a timely infringement action. The practical value of a listed formulation patent depends on:

• Whether the patent remains unexpired.
• Whether the patent is listed against the relevant strength and dosage form.
• Whether the generic applicant makes a Paragraph IV certification.
• Whether litigation is filed within the statutory period.
• Whether the patent survives invalidity and non-infringement challenges.
• Whether the generic formulation falls within the asserted claims.

Which companies are challenging or competing with Pemfexy?

Pemfexy competes with several categories of products:

1. Generic pemetrexed injection products.
2. Alimta and authorized or successor products.
3. Other ready-to-dilute or premixed pemetrexed presentations.
4. Hospital-compounded products.
5. Potential future formulations designed to avoid Pemfexy patent claims.

Major generic oncology companies with pemetrexed products have included Teva, Dr. Reddy’s Laboratories, Fresenius Kabi, Sagent Pharmaceuticals, and other FDA-approved manufacturers, depending on product strength and market period.[4]

Competition is based on more than wholesale acquisition price. Hospitals also evaluate:

• Vial size and dose efficiency.
• Short-dated inventory risk.
• Backorder history.
• FDA inspection and manufacturing record.
• Distribution reliability.
• Pharmacy labor savings.
• Contract pricing.
• 340B economics.
• Waste and hazardous-drug handling costs.

What Paragraph IV risks exist for Pemfexy?

A Paragraph IV challenge would be the most direct route for a generic applicant seeking to enter before expiration of an applicable listed patent. The applicant would assert that a listed patent is invalid, unenforceable, or not infringed.

For Pemfexy, the most likely technical design-around areas include:

• Use of a different buffer.
• Modified tromethamine concentration.
• Alternative pH range.
• Different pemetrexed concentration.
• Different vial overfill.
• Different container-closure system.
• Alternative sterilization or aseptic-processing method.
• Distinct post-dilution stability profile.

A design-around can reduce litigation exposure but may create regulatory and commercial tradeoffs. A different excipient system can affect stability, dilution compatibility, extractables, particulate formation, and shelf life. A generic applicant may prefer a formulation that avoids a narrow claim even if it requires additional development work.

How strong is the Pemfexy patent estate?

The estate is strongest where the claims are tied to measurable product characteristics that competitors are likely to reproduce, such as a defined pemetrexed concentration, pH range, buffer content, impurity profile, or stability result. It is weaker where claims depend on narrow process steps that can be avoided through an alternative manufacturing sequence.

Strength factors

• Ready-to-dilute liquid formulation with defined composition.
• Established clinical and regulatory history for pemetrexed.
• Commercially relevant reduction in pharmacy preparation steps.
• Potentially detectable product characteristics.
• Formulation differentiation after expiration of core Alimta protection.

Vulnerability factors

• Pemetrexed is an old and widely studied active ingredient.
• Sodium chloride and tromethamine are familiar pharmaceutical excipients.
• Generic manufacturers may have multiple formulation options.
• Obviousness challenges may rely on prior liquid formulations, buffer systems, or oncology injectable practices.
• Narrow claims may not block products using different excipient ratios or pH ranges.

Patent strength should be measured against the specific proposed competitor formulation, not against the product’s brand positioning.

What FDA regulatory status affects Pemfexy’s commercial opportunity?

Pemfexy received FDA approval for the same major indications as pemetrexed injection products, including mesothelioma and nonsquamous non-small-cell lung cancer.[1] It is administered intravenously after dilution.

The regulatory advantages of the product include:

• Established active ingredient.
• Familiar clinical dosing.
• No requirement to prove a new therapeutic mechanism.
• A liquid dosage form with a clear preparation benefit.
• Existing oncology treatment protocols that already include pemetrexed.

The main regulatory risks relate to sterile manufacturing, particulate control, container closure, extractables and leachables, stability after dilution, and inspection readiness. Injectable products face higher manufacturing barriers than oral solid-dose generics because contamination or visible and subvisible particles can trigger recalls, warning letters, or supply interruptions.

What commercial opportunities exist for Pemfexy excipients?

Hospital and infusion-center contracts

The strongest near-term opportunity is to quantify preparation savings. A supplier can position Pemfexy around:

• Reduced pharmacy compounding time.
• Fewer preparation steps.
• Lower reconstitution waste.
• Simplified standard operating procedures.
• More predictable dose preparation.

The value proposition must be supported by health-economic data rather than general convenience claims.

Regional licensing

Pemetrexed has a global clinical market, but regulatory requirements differ by jurisdiction. A ready-to-dilute formulation can be licensed to regional oncology companies that lack sterile injectable development capacity.

Potential licensing structures include:

• Territory-based commercialization rights.
• Supply agreements with minimum annual volumes.
• Co-development for local registration.
• Manufacturing technology transfer.
• Exclusive distribution with hospital contracting obligations.

Contract manufacturing

Sterile liquid oncology products require specialized equipment, validated aseptic processes, and hazardous-drug controls. Manufacturers with spare capacity can offer contract filling, secondary packaging, and regional release testing.

Presentation optimization

Commercially relevant presentation work includes:

• Additional vial sizes to improve dose-band matching.
• Low-dead-volume closures.
• Ready-to-administer infusion bags.
• Single-dose packaging with lower residual waste.
• Improved labeling for cytotoxic handling.
• Packaging configurations optimized for centralized pharmacy use.

Each change can create new regulatory, stability, and patent considerations.

Excipient-supplier opportunities

Excipient suppliers can compete through pharmaceutical-grade tromethamine, low-endotoxin sodium chloride, container-closure compatibility data, and technical support for sterile liquid development. The opportunity is strongest when a supplier can provide a complete package of:

• Compendial qualification.
• Impurity specifications.
• Extractables and leachables data.
• Stability support.
• Global regulatory documentation.
• Supply continuity.

How does Pemfexy compare with conventional pemetrexed products?

Attribute	Pemfexy	Conventional pemetrexed powder
Dosage form	Ready-to-dilute solution	Powder requiring reconstitution
Reconstitution step	Avoided	Required
Excipient strategy	Sodium chloride and tromethamine-based aqueous system	Product-specific excipient system after reconstitution
Pharmacy labor	Potentially lower	Higher preparation burden
Sterile manufacturing complexity	High	High, with lyophilization or powder filling
Patent differentiation	Liquid formulation and related claims	Often based on legacy product or generic approval
Main commercial advantage	Workflow and preparation efficiency	Lower acquisition price or established supply
Main commercial risk	Formulation-patent challenge and sterile supply risk	Price competition and commoditization

What litigation and settlement issues affect Pemfexy?

Litigation risk centers on Orange Book-listed formulation patents and Paragraph IV filings. A generic applicant can trigger patent litigation by certifying that a listed patent is invalid, unenforceable, or not infringed.

Possible settlement structures include:

• A delayed generic launch date.
• A license limited to a non-infringing formulation.
• Authorized-generic supply.
• Geographic restrictions.
• No-admission clauses.
• Volume or distribution limitations.

Settlement economics depend on patent remaining life, likely trial outcomes, market price erosion, and the number of competing applicants. If multiple generic manufacturers enter near the same date, price erosion can be materially greater than in a single-entrant scenario.

Publicly available sources do not establish a single, current market-wide conclusion on all Pemfexy-related litigation, settlements, or pending Paragraph IV filings. The Orange Book, FDA litigation records, PACER filings, and company securities disclosures govern the current legal position.[3,5]

What generic launch scenarios exist for Pemfexy?

Scenario 1: No successful early challenge

Pemfexy retains formulation-based protection until the relevant patent claims expire or are invalidated. Competition remains focused on conventional pemetrexed products.

Scenario 2: Single generic launch

A first entrant may obtain temporary commercial advantages, but hospital tenders and oncology distributor negotiations can rapidly reduce net pricing.

Scenario 3: Multiple generic launches

Several liquid pemetrexed products enter with different buffers or concentrations. Price becomes the primary purchasing factor, while supply reliability and vial efficiency determine contract retention.

Scenario 4: Formulation substitution

Hospitals use conventional powder products when the price difference exceeds pharmacy labor savings. Pemfexy’s value proposition weakens if labor is not separately measured or if oncology pharmacy capacity is underutilized.

What revenue exposure does Pemfexy create?

Pemfexy revenue is exposed to four variables:

1. U.S. pemetrexed treatment volume.
2. Conversion from conventional powder to ready-to-dilute liquid.
3. Net price after rebates, 340B discounts, and group-purchasing contracts.
4. Generic entry against Pemfexy’s formulation patents.

Product-specific Pemfexy revenue may not be separately disclosed in every public filing. Eagle Pharmaceuticals has reported product-level and company-level commercial information, but public disclosures do not always isolate net sales, gross-to-net deductions, or contribution margins for each Pemfexy presentation.[6]

A commercial model should therefore separate:

• Gross vial sales.
• Contracted hospital pricing.
• Wholesaler and distributor deductions.
• 340B exposure.
• Product returns.
• Expired inventory.
• Manufacturing and quality costs.
• Litigation and regulatory expenses.

Key Takeaways

• Pemfexy’s central differentiation is a ready-to-dilute liquid pemetrexed formulation.
• Sodium chloride and tromethamine support isotonicity, buffering, and pH control.
• The excipient strategy improves pharmacy workflow but does not change pemetrexed’s therapeutic mechanism.
• Commercial opportunities include hospital contracting, regional licensing, sterile contract manufacturing, and optimized vial or infusion presentations.
• Generic risk is driven by formulation-patent scope, Paragraph IV filings, design-around feasibility, and the number of potential entrants.
• Pemfexy has no biosimilar pathway because pemetrexed is a small-molecule drug.
• Revenue exposure depends heavily on hospital conversion, net pricing, 340B economics, and generic entry.
• The strongest barriers are sterile manufacturing capability, formulation know-how, stability data, and enforceable product-specific patents.

FAQs About Pemfexy Excipient Strategy and Market Opportunities

Does Pemfexy contain tromethamine?

Yes. Tromethamine is used as a buffering excipient in the Pemfexy aqueous formulation.[1]

Is Pemfexy preservative-free?

Yes. Pemfexy is supplied as a preservative-free, single-dose injectable product.[1]

Can a generic pemetrexed product use different excipients?

Yes. A competing product may use a different excipient system if it satisfies FDA requirements for pharmaceutical equivalence, safety, stability, compatibility, and quality, and does not infringe enforceable patent claims.

Is Pemfexy a biosimilar?

No. Pemfexy is a small-molecule pemetrexed drug, not a biologic. Competitors generally use generic-drug pathways rather than the biosimilar pathway.

What is the most attractive commercial improvement to Pemfexy?

The most practical opportunity is a presentation that reduces dose waste and pharmacy handling while preserving liquid stability, sterile assurance, and patent differentiation.

References

1. U.S. Food and Drug Administration. (2020). Pemfexy (pemetrexed injection) prescribing information.
2. U.S. Food and Drug Administration. (2024). Drugs@FDA: Alimta and pemetrexed products.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: Pemetrexed injection products.
5. U.S. Courts. (2024). PACER case locator and federal patent litigation records.
6. Eagle Pharmaceuticals, Inc. (2024). Annual report and securities filings.